[Evaluation of bone loss in patient treated with Gn-Rh analogs]
Related Experiment Videos
E Cassese1, V Piscitelli, A Farzati
1II Cattedra di Clinica Ostetrica e Ginecologica, Seconda Università degli Studi, Napoli.
Background:
The increasing use of analogs of Gn-RH during treatment of some benign gynaecological diseases, has induced the authors to investigate the principal collateral effects, fixing one's attention on the loss of bony mass.
Methods:
This perspective research has considered 38 patients selected for two diseases "endometriosis" and "uterine fibromyomatosis". The therapy has been effected with triptorelin intramuscularly in a dose of 3.75 mg every 28 days for six months, in all six phials.
Results:
After a half-yearly cycle of therapy, the loss of bony mass was valued about 3% medium.
Conclusions:
In the light of other studies too, it was decided to confirm the necessity of associating other medicines able to prevent the side effects caused by their analogs of Gn-RH.